Potential Therapeutic Use of Relaxin in Healing Cranial Bone Defects
Technical Report,20 Jul 2015,19 Jan 2019
University of Florida Gainesville United States
Pagination or Media Count:
The overall objective is to provide proof-of-principle that recombinant human relaxin rhRLX administration will accelerate bone healing in a calvarial defect model in mice by promoting angiogenesisvasculogenesis and osteogenesis, at least in part through incorporation of bone marrow-derived angio- and osteogenic progenitor cells into the lesion. Results from the second study conducted during this reporting period demonstrated reproducible implementation of uniform cranial lesions of approximately 1.5 mm diameter and circulating concentrations of relaxin ranging from 0.35-3.41 ngml. However, after 10-12 days of healing, the lesion closure was comparable in the relaxin- and vehicle-treated mice approximately 50 percent. Consistent with this finding is that there were also no significant differences in bonetissue volume percent or bone and tissues mineralization densities gcm3. Therefore, in the next study we will 1 reach a circulating concentration of relaxin administered systemically by s.c. osmotic pump between the first and second studies i.e., approximately 10-20 ngml in one group of mice 2 in another group, we will apply relaxin locally as collagen scaffolding 3 make a larger lesion of 3 rather than 1.5 mm diameter, in order to reduce the overall percent closure at 10-12 daysless closure may unmask differences between relaxin and vehicle treatments and 4 utilize old mice of approximately12 months of age, which relatively impaired bone healing due to age may be amenable to improvement by relaxin.
- Medicine and Medical Research